Companies / R1 Therapeutics
R1 Therapeutics
Redwood City, United States
R1 Therapeutics is developing innovative first-in-class therapies for patients with kidney disease, starting with lead asset AP306 for the treatment of hyperphosphatemia in patients with chronic kidney disease.
R1 Therapeutics, based in Redwood City, United States, has 3 investors on file, among them Abingworth, F-Prime Capital and SymBiosis Capital Management. Its latest round on record is Series A, 17 Mar 2026. Its site was last checked 13 Nov 2026: site answers.
Funding
1 round on recordRound sizes and total raised are on Fundup AI, our sister product for funding data.
Investors
3 investors on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital | |
| Page + round | Venture capital | |
| Portfolio page | Venture capital |
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get R1 Therapeutics and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Abingworth adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/r1therapeutics.com/investors
# also
GET /v1/companies/r1therapeutics.com
GET /v1/companies/r1therapeutics.com/news